High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon.
Alikhan
Mir
M
Spencer
Horace J
HJ
Kohli
Manish
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D018450:Disease Progression; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009392:Nephrectomy; D018579:Patient Selection; D011379:Prognosis; D011994:Recombinant Proteins; D015203:Reproducibility of Results; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins